Dexcom Inc
NASDAQ:DXCM

Watchlist Manager
Dexcom Inc Logo
Dexcom Inc
NASDAQ:DXCM
Watchlist
Price: 66.96 USD -2.87% Market Closed
Market Cap: 26.1B USD

Intrinsic Value

The intrinsic value of one DXCM stock under the Base Case scenario is 58.75 USD. Compared to the current market price of 66.96 USD, Dexcom Inc is Overvalued by 12%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DXCM Intrinsic Value
58.75 USD
Overvaluation 12%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Dexcom Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about DXCM?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is DXCM valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Dexcom Inc.

Explain Valuation
Compare DXCM to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Dexcom’s dominant position in continuous glucose monitoring faces mounting pressure from Abbott’s Freestyle Libre, which offers lower-cost options and wider distribution, potentially diluting Dexcom’s market share and pricing power.

Heightened reimbursement scrutiny might compress Dexcom’s margins; insurers could demand more cost-effective offerings, forcing the company to lower sensor prices or risk losing coverage status.

Failure to outpace competitor innovation may erode Dexcom’s technological advantage if rivals release superior long-wear or more seamless CGM solutions, undermining the brand’s leadership position.

Bull Theses

Dexcom’s recognized best-in-class accuracy and brand loyalty in Type 1 diabetes management could preserve its premium pricing and reinforce market leadership despite competitive threats.

The newly launched G7 system, significantly smaller and easier to use, has the potential to accelerate adoption in less-penetrated Type 2 diabetic segments and bolster strategic partnerships with insulin pump manufacturers.

Geographic expansion and growing acceptance of CGM in international markets should diversify Dexcom’s revenue base, mitigating reliance on the U.S. and fueling long-term top-line growth.

Show More Less
How do you feel about DXCM?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Dexcom Inc

Current Assets 5.2B
Cash & Short-Term Investments 3.3B
Receivables 1.2B
Other Current Assets 739.2m
Non-Current Assets 2.3B
PP&E 1.5B
Intangibles 103.1m
Other Non-Current Assets 652.1m
Current Liabilities 3.3B
Accounts Payable 451.5m
Accrued Liabilities 1.7B
Other Current Liabilities 1.2B
Non-Current Liabilities 1.4B
Long-Term Debt 1.3B
Other Non-Current Liabilities 143.4m
Efficiency

Free Cash Flow Analysis
Dexcom Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Dexcom Inc

Revenue
4.5B USD
Cost of Revenue
-1.8B USD
Gross Profit
2.7B USD
Operating Expenses
-1.9B USD
Operating Income
777.7m USD
Other Expenses
-57m USD
Net Income
720.7m USD
Fundamental Scores

DXCM Profitability Score
Profitability Due Diligence

Dexcom Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
Positive 3Y Average ROE
ROE is Increasing
Exceptional Gross Margin
62/100
Profitability
Score

Dexcom Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

DXCM Solvency Score
Solvency Due Diligence

Dexcom Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Negative Net Debt
Low D/E
80/100
Solvency
Score

Dexcom Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DXCM Price Targets Summary
Dexcom Inc

Wall Street analysts forecast DXCM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DXCM is 88.06 USD with a low forecast of 68.68 USD and a high forecast of 117.6 USD.

Lowest
Price Target
68.68 USD
3% Upside
Average
Price Target
88.06 USD
32% Upside
Highest
Price Target
117.6 USD
76% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dexcom Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for DXCM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

DXCM Insider Trading
Buy and sell transactions by insiders

DXCM News

Other Videos
What is the Intrinsic Value of one DXCM stock?

The intrinsic value of one DXCM stock under the Base Case scenario is 58.75 USD.

Is DXCM stock undervalued or overvalued?

Compared to the current market price of 66.96 USD, Dexcom Inc is Overvalued by 12%.

Back to Top